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ponent summary score as well as on the general health,
vitality, social functioning and role emotional domains of
the SF-36 (P  0.05). CONCLUSIONS: The results of
this interim analysis suggest that TM patients have a
lower quality of life than patients with EM.
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Patients who received at least one abortive migraine pre-
scription during July 1998 through December 1998 and
who had been continuously enrolled in a large west coast
health maintenance organization (HMO) for that period
were identified through the HMO pharmacy prescription
database and screened for eligibility criteria. Eligible
HMO patients were those who did not have any sensitiv-
ity nor contraindications to receiving Excedrin-migraine.
Patients from four medical groups in Southern California
were asked to participate based on the groups’ higher
than network migraine prescription utilization. Physician
groups who participated in the program consisted mainly
of primary care physicians or family practitioners and a
small proportion of neurologists. OBJECTIVE: To evalu-
ate the effects of an over-the-counter (OTC) migraine
medication on patient quality-of-life two and four months
after initiation therapy. METHODS: This was an obser-
vational study where enrolled patients received a one
month supply of Excedrin-migraine samples along with a
self-administered SF-36 questionnaire to complete at
baseline, months two and four. All data were analyzed
using SAS statistical software (version 6.12) with  set at
0.05. RESULTS: Results at month four indicated im-
provements in both MCS (P  0.05) and PCS scores. In
addition, there were improvements in seven of the eight
domains of the SF-36 with Role Physical, Bodily Pain, Vi-
tality and Social Functioning being significantly different
(P  0.05). CONCLUSION: In the four months after ini-
tiation of the OTC migraine program, quality-of-life
scores improved for the migraineurs enrolled in the
study.
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Length of therapy can affect clinical outcomes as well as
total healthcare costs that patients incur. Understanding
which factors influence length of therapy can be a major
step in managing treatment. OBJECTIVE: To identify
factors affecting length of antidepressant pharmacother-
apy for depression patients. METHODS: Using an em-
ployer claims database, antidepressant prescription claims
of 2,830 depression patients were analyzed for 18
months following their initial prescription for a SSRI/
SNRI, Newer Generation Antidepressant, or Tricyclic/
Tetracyclic in 1996. A wide range of demographic, pa-
tient- and prescription-level data were reviewed. Linear
regression modeling was implemented to model length of
antidepressant pharmacotherapy as a function of explan-
atory variables. RESULTS: The linear regression model
estimated length of prescription therapy as f (age, physi-
cian specialty prescribing medication, number of unique
drugs prescribed, starting drug therapy class, switch in
drug therapy class [yes/no], and number of gaps in ther-
apy). The model was significant (P  0.05) overall, as
was each regressor. Based on findings, the following in-
ferences can be made: (1) older patients underwent
longer therapy; (2) patients treated by a psychologist/
neurologist or both a primary care physician and a psy-
chologist/neurologist underwent longer therapy than pa-
tients treated by primary care physicians exclusively; pa-
tients treated by other physician specialties underwent
shorter therapy; (3) each additional, unique drug pre-
scribed resulted in longer total therapy; (4) patients ini-
tially treated with SSRIs/SNRIs had longer therapy than
patients initially treated with other antidepressant cate-
gories; and (5) each additional gap in therapy resulted in
progressively longer therapy. CONCLUSION: A positive
relationship was observed between the length of patient’s
antidepressant pharmacotherapy and a number of fac-
tors. A thorough understanding and management of
these factors could lead to improved patient outcomes.
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OBJECTIVE: To assess the treatment of childhood de-
pression in a managed care population. METHODS: All
subjects contained within Pharmetric’s Integrated Out-
comes database possessing a diagnosis of depression
(ICD-9-CM  296.2, 296.3, 300.4, 311) during 1997–98,
who were between 6–18 years of age at the time of diag-
nosis and were continuously enrolled for more than 1
year, were eligible for study inclusion. Utilization of psy-
chotherapy and pharmacotherapy during the 1-year pe-
riod following initial diagnosis was measured, as was de-
pression-related hospitalization. These measures were
compared across age categories (6–14, 15–18) and gen-
der, and hospitalization rates were compared across psy-
chotherapy and pharmacotherapy cohorts. RESULTS:
461 patients met the inclusion criteria. The mean age was
15.4 years and 51.4% of the sample was female. 96.5%
of patients received some type of pharmacotherapy,
while only 214 (46.4%) subjects received psychotherapy.
